Stephens Investment Management Group LLC Buys 186,670 Shares of Protagonist Therapeutics, Inc. $PTGX

Stephens Investment Management Group LLC increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 66.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 468,502 shares of the company’s stock after buying an additional 186,670 shares during the period. Stephens Investment Management Group LLC’s holdings in Protagonist Therapeutics were worth $66,007,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Keating Financial Advisory Services Inc. purchased a new stake in shares of Protagonist Therapeutics in the second quarter worth about $30,000. Allworth Financial LP purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at about $31,000. Quantbot Technologies LP purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at about $42,000. Parallel Advisors LLC lifted its position in Protagonist Therapeutics by 205.9% during the 3rd quarter. Parallel Advisors LLC now owns 361 shares of the company’s stock worth $51,000 after acquiring an additional 243 shares in the last quarter. Finally, Harbor Investment Advisory LLC purchased a new position in Protagonist Therapeutics in the 2nd quarter worth approximately $89,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Up 2.0%

PTGX stock opened at $127.16 on Thursday. Protagonist Therapeutics, Inc. has a fifty-two week low of $77.00 and a fifty-two week high of $160.81. The firm’s 50-day simple moving average is $139.10 and its 200 day simple moving average is $119.78. The stock has a market cap of $8.30 billion, a PE ratio of 26.94 and a beta of 1.21.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.57. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. The business had revenue of $274.41 million during the quarter, compared to the consensus estimate of $238.49 million. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current fiscal year.

Analyst Ratings Changes

PTGX has been the subject of a number of recent analyst reports. Leerink Partners started coverage on shares of Protagonist Therapeutics in a report on Monday, October 12th. They set an “outperform” rating and a $190.00 price target for the company. TD Cowen upped their price objective on shares of Protagonist Therapeutics from $155.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Wall Street Zen downgraded Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Barclays lifted their target price on Protagonist Therapeutics from $153.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 1st. Finally, The Goldman Sachs Group upgraded Protagonist Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $110.00 to $186.00 in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $166.67.

Read Our Latest Analysis on PTGX

Insider Buying and Selling

In related news, insider Arturo Molina sold 2,718 shares of the company’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $124.65, for a total transaction of $338,798.70. Following the transaction, the insider directly owned 81,397 shares of the company’s stock, valued at approximately $10,146,136.05. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Dinsesh Patel sold 63,548 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the transaction, the chief executive officer owned 522,968 shares in the company, valued at approximately $76,447,462.24. This represents a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 186,347 shares of company stock valued at $26,891,786. Company insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

(Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Featured Stories

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.